Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07440706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome

Study acronym: iCan3 Dumping
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 27, 2026 (before its estimated October 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Late dumping syndrome is a common complication following Roux-en-Y gastric bypass, characterized by postprandial hypoglycemia with significant impact on patient safety and quality of life. Traditional capillary glucose monitoring has limited ability to detect rapid glycemic fluctuations. This prospective randomized study aims to evaluate the efficacy and safety of the iCan i3 continuous glucose monitoring (CGM) system compared to conventional capillary glucose monitoring in detecting hypoglycemic events in post-bariatric patients with late dumping syndrome. Participants will be randomized into two groups: one using CGM and one using standard fingerstick monitoring, and followed for 60 days. Clinical outcomes, hypoglycemia frequency, symptom correlation, and quality of life will be assessed.
Trial Details
NCT Number NCT07440706
Lead Sponsor Kaiser Clinic and Hospital
Conditions
(from sponsor)		 Dumping Syndrome, Post-bariatric Hypoglycemia
Related terms Dumping Syndrome, Hypoglycemia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov